Primary neonatal outcome: Composite of the following
Neonatal death | RDS | Grades III or IV IVH |Sepsis | NEC | ROP
9,867 women were included in the study
1,038 women underwent preterm births
Maternal Adverse Events
Composite maternal outcome was more frequent in IPTB (4.4%) vs SPTB (0.9%)
adjusted odds ratio [aOR], 4.0 (95% CI, 1.4–11.8)
Blood transfusion was more common in IPTB (3.4%) vs SPTB (0.9%); P=0.005
aOR 3.2 (95% CI, 1.1-9.8)
Prolonged hospital stay was more frequent in ITPB (8.7%) vs SPTB (1.8%); P<0.001
aOR 3.7 (95% CI, 1.8-7.7)
Newborn Adverse Events
Composite neonatal outcome was less frequent in IPTB (22.6%) vs SPTB (24.1%) but when adjusted for confounders inlcuding demographics and peripartum infections, risk increased
aOR, 1.8 (95% CI, 1.1–3.0)
Other outcomes that were increased in IPTB vs STB group
RDS: aOR 1.7 (95% CI, 1.1-2.7)
SGA <5th percentile: aOR 7.9 (95% CI, 4.0-15.7)
NICU admission: aOR 1.8 (95% CI, 1.3-2.5)
Crude risk of death higher in SPTB
Most frequent reason for IPTB was pregnancy-associated hypertension
Outcomes for this indication only were similar to the overall group, except that neonatal composite and RDS were no longer statistically different
IPTB vs SPTB have a fourfold higher incidence of maternal adverse events
The authors state that based on the results of this study “interventions to prevent the underlying causes of IPTBs such as preeclampsia, to reduce the risk of IPTBs and hence reduce the associated burden of adverse outcomes may deserve as much attention as directed toward SPTBs”
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan